JP7420791B2 - ハイリスクヒトパピローマウイルス感染症の治療 - Google Patents

ハイリスクヒトパピローマウイルス感染症の治療 Download PDF

Info

Publication number
JP7420791B2
JP7420791B2 JP2021510859A JP2021510859A JP7420791B2 JP 7420791 B2 JP7420791 B2 JP 7420791B2 JP 2021510859 A JP2021510859 A JP 2021510859A JP 2021510859 A JP2021510859 A JP 2021510859A JP 7420791 B2 JP7420791 B2 JP 7420791B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
patient
per
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021510859A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020043762A5 (https=
JP2021536454A (ja
JP2021536454A5 (https=
Inventor
ノルベルト フィッツ、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SELO MEDICAL GmbH
Original Assignee
SELO MEDICAL GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SELO MEDICAL GmbH filed Critical SELO MEDICAL GmbH
Publication of JP2021536454A publication Critical patent/JP2021536454A/ja
Publication of JPWO2020043762A5 publication Critical patent/JPWO2020043762A5/ja
Publication of JP2021536454A5 publication Critical patent/JP2021536454A5/ja
Application granted granted Critical
Publication of JP7420791B2 publication Critical patent/JP7420791B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021510859A 2018-08-28 2019-08-28 ハイリスクヒトパピローマウイルス感染症の治療 Active JP7420791B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18191289.0A EP3616693A1 (en) 2018-08-28 2018-08-28 Therapy of high-risk human papillomavirus infections
EP18191289.0 2018-08-28
PCT/EP2019/072926 WO2020043762A1 (en) 2018-08-28 2019-08-28 Therapy of high-risk human papillomavirus infections

Publications (4)

Publication Number Publication Date
JP2021536454A JP2021536454A (ja) 2021-12-27
JPWO2020043762A5 JPWO2020043762A5 (https=) 2022-08-10
JP2021536454A5 JP2021536454A5 (https=) 2022-08-10
JP7420791B2 true JP7420791B2 (ja) 2024-01-23

Family

ID=63442535

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510859A Active JP7420791B2 (ja) 2018-08-28 2019-08-28 ハイリスクヒトパピローマウイルス感染症の治療

Country Status (25)

Country Link
US (2) US20210299163A1 (https=)
EP (2) EP3616693A1 (https=)
JP (1) JP7420791B2 (https=)
CN (1) CN112584828A (https=)
AR (1) AR116027A1 (https=)
AU (1) AU2019332079B2 (https=)
BR (1) BR112021003360A2 (https=)
CA (1) CA3107691C (https=)
CL (1) CL2021000197A1 (https=)
EA (1) EA202190441A1 (https=)
ES (1) ES2958808T3 (https=)
GE (2) GEAP202215586A (https=)
HR (1) HRP20231470T1 (https=)
HU (1) HUE064691T2 (https=)
IL (1) IL281080B2 (https=)
MA (1) MA53482B1 (https=)
MD (1) MD3843715T2 (https=)
MX (1) MX2021002310A (https=)
PL (1) PL3843715T3 (https=)
RS (1) RS64916B1 (https=)
SM (1) SMT202300340T1 (https=)
TW (1) TWI827652B (https=)
UA (1) UA127632C2 (https=)
WO (1) WO2020043762A1 (https=)
ZA (1) ZA202100375B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3875083A1 (en) * 2020-03-03 2021-09-08 Selo Medical GmbH Composition for use in a treatment of cervical cell abnormalities comprising selenite compound and acid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518758A (ja) 2001-02-13 2004-06-24 オーコファーム フォーシュンクス−ウント エントウィックルングス−ゲゼルシャフト ミット ベシュレンクテル ハフトング 亜セレン酸塩またはセレン酸塩を含有する製剤の使用
US20130323328A1 (en) 2011-02-16 2013-12-05 Selo Medical Gmbh Pharmaceutical Preparation Containing Selenite or Selenite-Containing Compounds for Treating Cervical Dysplasia or Carcinomas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2245301C2 (ru) 2000-05-10 2005-01-27 Окофарм Форшунгс-Унд Энтвиклюнгс-Гмбх Способ уменьшения площади поверхности диоксида кремния
AT412758B (de) 2000-06-05 2005-07-25 Vis Vitalis Lizenz & Handels Verwendung einer selenithältigen lösung zur behandlung viraler erkrankungen
AT412703B (de) * 2001-12-04 2005-06-27 Vis Vitalis Lizenz & Handels Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518758A (ja) 2001-02-13 2004-06-24 オーコファーム フォーシュンクス−ウント エントウィックルングス−ゲゼルシャフト ミット ベシュレンクテル ハフトング 亜セレン酸塩またはセレン酸塩を含有する製剤の使用
US20130323328A1 (en) 2011-02-16 2013-12-05 Selo Medical Gmbh Pharmaceutical Preparation Containing Selenite or Selenite-Containing Compounds for Treating Cervical Dysplasia or Carcinomas
JP2014505708A (ja) 2011-02-16 2014-03-06 セロ メディカル ゲゼルシャフト ミット ベシュレンクテル ハフツング 子宮頚部の異形成または癌腫の治療用の亜セレン酸あるいは亜セレン酸イオン含有化合物を含有する医薬調製物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Gynecologic Oncology，2011年，Vol.122，p.303-306
Modern Pathology，2006年，Vol.19，p.384-391
The American Journal of Surgical Pathology，2001年，Vol.25, No.7，p.884-891

Also Published As

Publication number Publication date
CN112584828A (zh) 2021-03-30
CA3107691A1 (en) 2020-03-05
JP2021536454A (ja) 2021-12-27
GEP20227432B (en) 2022-10-25
EA202190441A1 (ru) 2021-06-15
MD3843715T2 (ro) 2023-12-31
AU2019332079B2 (en) 2024-08-29
CA3107691C (en) 2024-10-29
EP3616693A1 (en) 2020-03-04
RS64916B1 (sr) 2023-12-29
IL281080A (en) 2021-04-29
EP3843715A1 (en) 2021-07-07
WO2020043762A1 (en) 2020-03-05
IL281080B1 (en) 2024-08-01
HUE064691T2 (hu) 2024-04-28
US20250281524A1 (en) 2025-09-11
ZA202100375B (en) 2024-08-28
TWI827652B (zh) 2024-01-01
AR116027A1 (es) 2021-03-25
BR112021003360A2 (pt) 2021-05-11
EP3843715B1 (en) 2023-09-13
PL3843715T3 (pl) 2024-02-19
MA53482B1 (fr) 2023-11-30
UA127632C2 (uk) 2023-11-08
MA53482A (fr) 2021-07-07
ES2958808T3 (es) 2024-02-15
MX2021002310A (es) 2021-04-28
IL281080B2 (en) 2024-12-01
US20210299163A1 (en) 2021-09-30
HRP20231470T1 (hr) 2024-03-01
SMT202300340T1 (it) 2023-11-13
EP3843715C0 (en) 2023-09-13
TW202023534A (zh) 2020-07-01
CL2021000197A1 (es) 2021-09-20
AU2019332079A1 (en) 2021-02-11
GEAP202215586A (en) 2022-06-27

Similar Documents

Publication Publication Date Title
US20250281524A1 (en) Therapy of high-risk human papillomavirus infections
Baghi et al. Cancers associated with human papillomavirus: an overview of prevalence in Iran and the Middle East
CN107582563B (zh) 用于治疗子宫颈非典型性增生或子宫颈癌的包含亚硒酸盐或含亚硒酸盐化合物的药物制剂
Zang et al. Risk factors associated with the persistence of human papillomavirus after cervical excision in patients with high-grade squamous intra-epithelial neoplasia
JP7840859B2 (ja) 子宮頸部細胞異常の治療に使用するための組成物
CA3167015C (en) Composition for use in a treatment of cervical cell abnormalities comprising selenite compound and acid
EA042677B1 (ru) Терапия папилломавирусных инфекций человека высокого риска
EA048333B1 (ru) Терапия папилломавирусных инфекций человека высокого риска
HK40045218A (en) Therapy of high-risk human papillomavirus infections
HK40045218B (en) Therapy of high-risk human papillomavirus infections
EA048159B1 (ru) Композиция для применения в лечении аномалий цервикальных клеток, содержащая селенитовое соединение и кислоту
HK40074763B (en) Composition for use in a treatment of cervical cell abnormalities comprising selenite compound and acid
HK40074763A (en) Composition for use in a treatment of cervical cell abnormalities comprising selenite compound and acid
Stępień et al. Current knowledge of cervical cancer: pathogenesis, prevention, and treatment. Part I

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230929

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240111

R150 Certificate of patent or registration of utility model

Ref document number: 7420791

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150